Petrelintide
Also known as ZP8396
One-dose burn-down
Half-life
10.0 days
Tmax
3.0 days
Bioavailability
85%
Steady state
~49d
Typical dose
1.2 mg
Investigational long-acting amylin analog for obesity, designed for once-weekly subcutaneous dosing (often studied alongside GLP-1 agonists).
Mechanism of action
Amylin-receptor agonism promotes satiety and slows gastric emptying, complementing GLP-1 pathways.
Investigational — not approved. Terminal half-life ~10 days (once-weekly dosing); ~85% bioavailability.
Track Petrelintide for free
Log your doses and PeptideBuddy models Petrelintide's half-life into a live chart so you always know how much is active — plus reminders, reconstitution and protocol planning.
Start tracking free